Shares of animal health company Elanco (NYSE:ELAN) jumped 9.5% in the afternoon session after the company reported third-quarter 2026 results and raised its full-year guidance.
Elanco's pricing held firm in Q3 while rivals discounted, a choice that tests whether proprietary products can continue to win share without cutting prices.
Elanco Animal Health (ELAN) has just put fresh numbers on the table. Third quarter 2026 sales reached US$1.27b, with net income of US$18m and a move back into positive earnings per share. The stronger third quarter has landed against a backdrop of rising optimism around Elanco Animal Health, with a 1-day share price return of 8.7% and a 30-day share price gain of 15.1% building on a 19.8% 1-year total shareholder return and a very large 3-year total shareholder return of about 14x, although...
Elanco Animal Health Inc (ELAN) beat the high end of guidance with 9% organic growth, 40% innovation revenue growth, and a raised full-year outlook.
Animal health company Elanco (NYSE:ELAN) beat Wall Street’s revenue expectations in Q3 2026, with revenue up 11.3% year on year to $1.27 billion. Guidance for next quarter’s revenue was better than expected at $1.2 billion at the midpoint, 1.3% above analysts’ consensus estimates. Its non-GAAP profit of $0.27 per share was 32.8% above analysts’ consensus estimates.
Detailed price information for Iqvia Holdings Inc (IQV-N) from The Globe and Mail including charting and trades.
Detailed price information for Elanco Animal Health Inc (ELAN-N) from The Globe and Mail including charting and trades.
Elanco Animal Health (NYSE:ELAN) held its second-quarter earnings conference call on Wednesday. Below is the complete transcript from the call. Benzinga APIs provide real-time access to earnings call transcripts and
Elanco Animal Health (NYSE:ELAN) President and CEO Jeff Simmons outlined the company’s growth strategy, product launches, deleveraging plans and outlook for its pet health and farm animal businesses during the Bank of America Healthcare Conference in London. Simmons said Elanco delivered 10% report
Elanco Animal Health Incorporated (NYSE: ELAN) will attend the BofA Securities Global Healthcare Conference 2026 on September 22, 2026. Jeff Simmons, president and CEO, will participate in a fireside chat on Tuesday, September 22 at 2:10 p.m. BST (9:10 a.m. EDT).
Elanco Animal Health (ELAN) drew fresh attention after its latest closing price of US$23.17. This put recent share moves and the company’s improving annual revenue and net income figures in sharper focus for investors. Recent moves show mixed momentum for Elanco Animal Health, with a 1-day share price return of 1.36% but a 7-day share price return down 5.43%. However, the 1-year total shareholder return of 24.30% and 3-year total shareholder return of 96.36% point to a much stronger...
Elanco Animal Health Incorporated (NYSE: ELAN) will announce its third quarter 2026 financial results on Friday, November 6, 2026. Elanco will also conduct a conference call on that day with the investment community and media to further detail the company's performance.
Elanco Animal Health Incorporated (NYSE: ELAN) will attend the Morgan Stanley 24th Annual Global Healthcare Conference on September 15, 2026. Jeff Simmons, president and CEO, Bob VanHimbergen, executive vice president and CFO, and Bobby Modi, executive vice president U.S. Pet Health and Global Digital Transformation will participate in a fireside chat on Tuesday, September 15 at 2:35 p.m. ET.
Purchasing 40,000 shares is a bullish signal for shareholders.
The completed 25,000-square-foot Elwood site expansion bolsters 's monoclonal antibody (mAb) production; supports delivery of next-generation pipelineINDIANAPOLIS, IN / ACCESS Newswire / August 31, 2026 / Animal Health Incorporated (NYSE:ELAN) announced the on-time completion of a 25,000-square-foot manufacturing expansion of its Elwood, Kansas manufacturing site. As one of only two animal health companies with mAb solutions on the market today, the expansion further strengthens 's leadership in
ELWOOD, Kan. (News-Press NOW) — Elanco Animal Health recently completed a $120 million expansion of its Elwood manufacturing facility, quadrupling production capacity at a site that company leaders say will play a central role in developing and producing the next generation of animal health treatments. Company, state and federal officials gathered Wednesday to celebrate completion of the ...
Detailed price information for Elanco Animal Health Inc (ELAN-N) from The Globe and Mail including charting and trades.
This is the newest page. Registered accounts read further back.